IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 768
NA - Nord America 747
AS - Asia 212
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 740
PL - Polonia 275
IE - Irlanda 173
SE - Svezia 125
IT - Italia 107
CN - Cina 97
SG - Singapore 73
FR - Francia 38
VN - Vietnam 18
BE - Belgio 16
FI - Finlandia 15
ID - Indonesia 10
BR - Brasile 7
CA - Canada 7
IN - India 7
UA - Ucraina 7
GB - Regno Unito 5
DE - Germania 4
KR - Corea 4
CO - Colombia 2
AE - Emirati Arabi Uniti 1
ES - Italia 1
EU - Europa 1
IR - Iran 1
JP - Giappone 1
NL - Olanda 1
NO - Norvegia 1
Totale 1.737
Salva come PNG Salva come JPEG
Città #
Warsaw 272
Dublin 173
Chandler 168
Nyköping 67
Singapore 49
Ann Arbor 43
Messina 42
New York 36
Dearborn 34
Princeton 34
Ashburn 33
Beijing 32
Jacksonville 32
Medford 26
Des Moines 23
Dong Ket 18
Brussels 16
Cambridge 16
Fort Washington 14
Wilmington 14
Jinan 11
Jakarta 10
Houston 8
Shenyang 8
Woodbridge 8
Boardman 7
Falls Church 7
San Mateo 7
Guangzhou 5
Hebei 5
Nanjing 5
Pune 5
Seattle 5
Toronto 5
Anagni 4
Cagliari 4
Dongdaemun-gu 4
Fairfield 4
Nanchang 4
Redwood City 4
Zhengzhou 4
Brockport 3
Hangzhou 3
London 3
Los Angeles 3
Radomsko 3
Santa Clara 3
Auburn Hills 2
Bogotá 2
Camaçari 2
Girifalco 2
Helsinki 2
Milan 2
Shanghai 2
Taizhou 2
Tianjin 2
Venice 2
Abu Dhabi 1
Achim 1
Amsterdam 1
Ardabil 1
Bergamo 1
Bollate 1
Calgary 1
Catania 1
Centuripe 1
Changsha 1
Chengdu 1
Ciampino 1
Cupertino 1
Florianópolis 1
Frankfurt am Main 1
Fuzhou 1
Huzhou 1
Hyderabad 1
Jandira 1
Kunming 1
Lanzhou 1
Marina di Montemarciano 1
Monmouth Junction 1
Ningbo 1
Nishinomiya 1
Norwalk 1
Oslo 1
Ottawa 1
Riva 1
Santo André 1
Scicli 1
Shenzhen 1
Taiyuan 1
Tappahannock 1
Taubaté 1
The Dalles 1
Unaí 1
Vigo 1
Villeneuve-le-roi 1
Zhoushan 1
Totale 1.344
Salva come PNG Salva come JPEG
Nome #
Exosomal PD-L1 expression and dynamic changes of immune response associated cytokines as predictive biomarkers for immune checkpoint blockage with PD-1/PD-L1 inhibitors in advanced/metastatic non-small cell lung cancer 156
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 106
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 95
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 91
NSCLC and HER2: between lights and shadows 83
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 82
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 81
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 80
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 79
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 78
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 77
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 74
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 73
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 72
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 65
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 56
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 55
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 50
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 49
Liquid biopsy tracking of lung tumor evolutions over time 49
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 40
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario 39
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 38
Acquired resistance in oncogene-addicted non-small-cell lung cancer 38
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 38
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 31
How I treat ALK-positive non-small cell lung cancer 30
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 22
Totale 1.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020203 0 0 0 0 2 48 20 22 16 25 27 43
2020/2021426 15 31 39 54 77 25 46 25 35 49 10 20
2021/2022226 1 24 7 7 9 9 14 9 1 39 35 71
2022/2023527 37 56 19 44 35 47 7 45 217 3 12 5
2023/2024146 8 25 8 9 12 58 2 10 1 1 0 12
2024/2025109 3 5 7 36 58 0 0 0 0 0 0 0
Totale 1.827